In this study, we reported for the first time that FPRL2 mediates Adriamycin resistance in breast cancer using public database mining, and breast cancer cell lines and utilizing a combination of bioinformatics and molecular biology experimental techniques. The gene discussed is FPR3; the disease is breast carcinoma.